Unicycive Therapeutics, Inc.
NASDAQ: UNCY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shalabh K. Gupta
- Employees
- 22
- Headquarters
- Los Altos, United States
- IPO year
- 2021
- Market cap
- $169.6M
- Website
- https://www.unicycive.com
Loading UNCY…
Loading profile data…Frequently asked questions about UNCY
What does Unicycive Therapeutics, Inc. (UNCY) do?
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is...
Where does UNCY trade?
Unicycive Therapeutics, Inc. (UNCY) trades on the NASDAQ Capital Market.
What sector is UNCY in?
Unicycive Therapeutics, Inc. (UNCY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Unicycive Therapeutics, Inc.?
Shalabh K. Gupta is the chief executive officer of Unicycive Therapeutics, Inc. (UNCY).
Where is Unicycive Therapeutics, Inc. headquartered?
Unicycive Therapeutics, Inc. is headquartered in United States.
Does UNCY pay a dividend?
Unicycive Therapeutics, Inc. (UNCY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did UNCY go public?
Unicycive Therapeutics, Inc. (UNCY) completed its initial public offering in 2021.